BrainStorm's participation in this year's summit marks a critical juncture for the company as it prepares to launch its Phase 3b clinical trial of NurOwn, supported by a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), which affirms that the trial's design and statistical analysis are adequate to support a future marketing application if successful. About Brainstorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leading developer of autologous ...